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Abstract
Based on the similarity In primary structure between the newly characterized ligand for CD40
(CD40L) and the tumor necrosis factors (TNFs), we have modeled a detailed 3-D structure for
CD40L. We used the known structure of TNFa as a template for the generation of the CD40L
model. The soundness of the model-bulldlng algorithms was verified by constructing a 3-D model
of TNF/3 and comparing It to Its crystallographlcally determined structure. The CD40L sequence Is
entirely compatible with the 'jelly-roll' /3-strand structure characteristic of the TNFs. Like the TNFs,
CD40L Is predicted to form a compact trimer, although the Interactions between monomers are
distinct from those found In the TNFs. The model predicts which regions of CD40L could Interact
with Its receptors) and which amlno acids are essential for the maintenance of Its trimerlc
structure.
CD40 is a transmembrane glycoprotein expressed by B
lymphocytes, but also detected on other cell types or tumors,
particularly carcinomas (1). The functional characterization of CD40
has been limited to B lymphocytes, where it seems to play a key
role in T cell-mediated and antigen-driven activation. Immobilized
antibodies against CD40 have a number of striking effects on B
cells: in synergy with agents that engage the antigen receptor and
IL-4, they can induce long-term proliferation and homotypic
adhesion, prevent the normal apoptotic death which occurs in
germinal centers, induce the transcription of germline Ig constant
regions, and activate ctass switching, particularly to IgE (2-6). To
a large extent these effects are similar to those induced by activated
T helper cells.
CD40 is a member of a growing family of receptors having a
characteristic pattern of cysteine-rich repeats in their extracellular
domains (7). Other members of the family incude the low-affinity
nerve growth factor (NGF) receptor, the two receptors for the tumor
necrosis factors (TNFa and TNF/3), and several membrane-
anchored proteins whose ligands remain to be identified (0X40,
4 -1BB, CD27, and the fas antigen). Pox viruses also encode
soluble proteins related to the type IITNF receptor, which have been
shown to bind TNF (8,9). Recently, Armitage and coUeagues cloned
the CD40 ligand (CD40L) using a CD40/lgFc recombinant hybrid
as a probe (10). They showed that CD40L is a class II
transmembrane protein, specifically expressed on activated CD4+
T lymphocytes, which efficiently mimics the effects of anti-CD40
antibodies when presented by transfected non-T cells. These results
strongly suggest that CD40L-CD40 interactions play an important
role in the T helper function, which requires direct T cell-B cell
contacts.
Although the fact that CD40L could be related to TNFa and TNF/3
was not immediately realized (10), the similarity between the three
proteins has recently become apparent (11). When we used the
BLAST server at the National Center for Biotechnology Information
to search for similarities between the CD40L sequence and those
deposited in the protein databases (12), we found the group of
TNFas to be the most similar at the primary sequence level, followed
by the TNF/3s. To explore this relationship in more detail, we
performed multiple pairwise alignments using the laJign and tfasta
algorithms (13). The alignment we generated (Fig. 1) differs from
that published by Farr^h and Smith (11) in the positions of the gaps,
which were inserted so as to maximize the similarity in tertiary
structure. The degrees of identity of murine CO40L with murine and
human TNFa are 23.2 and 25.7% respectively, and with TNF/3 20.0
and 24.3%. This compares to" a 30.6% identity between human
TNFa and TNF/3, whose 3-D structures display only a 0.61 A
r.m.s. positional deviation (14). A high degree of structural
conservation with a tow similarity at the-primary sequence level is
not without precedent among proteins with a high /3-strand content:
among the a2-microglobulins, the sequences of the bilin- and
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Fig. 1. Alignment of the primary sequence of CD40L with TNFa and TNF0. The alignment was optimized to be congruent with the superposition of
3-D structures. Amino acid numbering is relative to the initiation codon, and corresponds to SwissProt database conventions. The alignments starts
at the N-terminus of the secreted form of TNFa. Residues conserved between two proteins are capitalized; those conserved between all three are in
boldface. Shading marks the positions in TNFa and TNF0 that are known to affect receptor binding (25,26). The cysteines participating in disuifide
bonds are marked in white on black. The ^-strands are boxed and labeled according to Eck et al. (14,18). The short a-helix in the G - H connecting
region is ateo marked.
Qte$
Fig. 2. Stereo representation of the superimposed a-carbon backbones of CD40L (thick line) and TNFa (thin line). Boldface amino acid positions are
from the CD40L sequence. The disuifide bonds in CD40L (bold) and TNFa (thin) are marked.
retinol-binding proteins are only 16% identical, yet they differ by
<2 A r.m.s. in the a-carbon backbone of their 3-D structures
(15,16). Therefore, it seemed reasonable to attempt to build a 3-D
model for CD40L based on the known structure of TNFa.
As a tool to this end, we used the ProMod knowtedge-based
molecular modeling package [M. C. Peitsch, manuscript in
preparation; ProMod is freely available from the authors (E-mail:
peitsch@ulbiol.unil.ch), and has been implemented on various Unix
platforms as well as under VMS], which integrates aO of the foBowing
modeFBuilding steps exce'pl fhe~eriergy mTnTmczafibh'ralcTjlaifJonsT"
(0 construction of an averaged framework (17) from the three
monomers in the TNFa trimer [entry 1TNF in the Brookhaven Protein
Databank (PDB)] (18,19). (ii) fitting of the CD40L monomer
backbone onto this framework using a primary sequence alignment
optimized for 3-D similarity (Fig. 1). (i) Recxyistructjon of loop regions
from their 'stems' by structural homotogy searches through the PDB
databank, as described by Greer (20). (rv) Rebuilding of missing
side chains using a library of allowed rotamers (21). (v) Optimization
of bond geometries and relief of unfavorable non-bonded contacts
by 30 steps of steepest descent followed by 500 steps of conjugate
gradient minimization using the CHARMM program (22) with the
PARAM19 parameter set (vi) Superimposition of three copies of
"fie"o"p^Eea^rnonOTneTstnjcture"onTo"^ie"TNFa"trtmer7 foflowetf
by another 200 steps of conjugate gradient minimization, (vn)
Analysis of the resulting monomer and trimer structures using the
3-D profile matching procedure of LCrthy et al. (23).
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Fig. 3. Proffle window plots for the TNFa and CD40L monomers (A and B) and trimers (C and D). The plots were calculated using a sliding window
size of 21 to average the 3-D- 1-D scores of individual amino acids. The average score is indicated by a stippled horizontal line.
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The final calculated CD40L monomer structure (coordinates of
which have been deposited with the Brookhaven Protein Database)
deviates from its non-minimized form by 0.52 A r.m.s. and from
the TNFa a-carbon backbone by 0.80 A r.m.s. (Fig. 2). Verification
of the monomer structure using the 3-D profile procedure (23)
reveals two regions with scores falling below 0.1, which reflect
unfavorably exposed non-polar surfaces (Rg. 3B). One such region
ateo exists in the TNFa monomer structure (Fig. 3A), but none
appear in the profiles of the TNFa or CD40L trimers (Fig. 3C and
D^-Upon trimerization, the apolar surfaces that appear as low-
Fig. 4. Tertiary structures of the TNFa, TNF/3, and CD40L trimers. The
Ribbons program was used to display the arrangement of /S-sheets (flat
ribbon-like regions) and the loops connecting them in the three molecules.
The disulfide bonds that stabilize the TNFa and COWL structures but are
absent from TNF/3 are ateo depicted. The pictures of TNFa and TNF/3 are
based on their crystallographicaDy determined structures (14,18).
scoring areas in the monomer profiles participate in the contacts
between subunits or are buried in regions from which water is
excluded. In order to verify the validity of our modeling procedures,
we constructed a 3-D model of TNF/3 from the alignment shown
in Fig. 1, using the same procedures as for CD40L. The modeled
TNF/3 trimer differed from its crystaDographically determined structure
(kindly provided by S. R. Sprang) by 0.95 A r.m.s., with most of
the differences confined to the unconstrained loops connecting the
jS strands. These results are indicative of a good-quality model with
no major folding incompatibilities, and are strong evidence that
CD40L exists as a native trimer, similar to TNFa and TNF0.
Although it is generally similar to the structure of TNFa and adopts
the same 'jelly-roU' connectivity between /3-strand regions (18,19),
the modeled CD40L structure differs from it in several important
ways (Figs 2 and 4). First, the loop connecting the E and F strands
is shorter by seven residues, similar to the structure of TNF/3 (14).
As in TNF/3, this is accompanied by the disappearance of the
disulfide bond (TNFa: Cys145-Cys177; note that all residue
numbering is relative to the initiation codon and not the N-terminus
of the 'mature' form) that holds together the E - F and C - D loops
in TNFa. However, another disulfide bond which directly links the
C and F strands (CD40L: Cys177 - Cys217) stabilizes this regbn
in CD40L. Compared to TNFa, the A - A ' loop is longer by two
residues, while the D - E loop and the G - H linkers are shorter by
one, without any major effects on the structure. The C - D loop,
which is longer in TNF/3, is conserved between CD40L and TNFa.
The D-E loop regions of TNFa and TNF/3 are exposed to the
outside and contain several residues known to influence receptor
binding (Figs 1 and 5). This region is ateo exposed in CD40L and
therefore accessible to contacts with the receptor (see below).
^mentioned above, CD40L almost certainly exists as a trimer
in its native form. An examination of the monomer contact areas
in our CD40L trimer model reveals some interactions which differ
from the aromatic tiling and hydrophobic interactions predominating
in the contact surfaces between the TNFa or TNF/3 monomers
(14,18,19). The Tyr169 residues are of particular interest, being in
a perfect conformation to form three hydrogen bonds bracketing
the 3-fold axis (Fig. 6). Just below these tyrosines, three histidines
which are absent from TNFa or TNF/3 ateo form close contacts.
Rg. 5. Stereo view of the CCMOL trimer a-carbon backbone down the 3-fold axis. Amino acids homologous to those that influence TNFa receptor
binding are marked with black circles, and the corresponding residues in TNFa are indicated.
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Other hydrophobe interactions are similar to those found in TNFa
and /S. The bottom part of the trimer, as in the TNFs, is stabilized
by multiple polar interactions and salt bridges.
TNF/3 recently has been shown to dock into the type II TNF
receptor with the tip of its conical structure facing the cell membrane.
This leads to the prediction that in TNFa and CD40L, both of which
are type II membrane-anchored proteins (10,24), the N-terminal part
of the trimer would face towards the base of the cone, which is
proximal to the cell membrane. This prediction is borne out both
in the crystal structures of TNFa and TNF/3 (14,18,19) and in our
model f a CCMOL The specificity of the interactions between the
TNFs and their receptors has been studied in some detail by
random and directed mutagenesis of the ligands (25,26). In both
TNFa and TNF/3, this approach has localized receptor contacts in
the lower portion of the cone, in an area covering a contact surface
between monomers. Surprisingly, there is very little residue
conservation between TNFa and TNF/3 in this area, making it difficult
to predict relevant ligand - receptor contacts. The homologous
region in CD40L is again very different from the TNFs': only one
TNFa residue important for receptor binding is conserved in CD40L
(Figs 1 and 5). It is worth noting that the necessity of cross-linking
or immobilizing anfj-CD40 antibodies to give them biological activity
led to the speculation that the CD40 ligand should be at least a
dimer. This is amply borne out by our model.
The main conclusion to be drawn from the model is that CD40L
is no more different from TNFa or TNF/3 than they are from each
other. Similarly, the types I and II TNF receptors (TNF-RI and TNF-
Rll) do not resemble each other more than they do CD40, at least
at the primary sequence level. In fact, construction of a similarity
tree of the TNF receptor family using the PileUp program of the
GCG package (27) indicates that CD40 is more closely related to
TNF-RII than TNF-RI is to TNF-RII. Thus, we can identify a family
of three receptors (TNF-RI, TNF-RII, and CD40) and three ligands
(TNFa, TNF|8, and CD40L) which do not show any obvious
structural constraints as to possible mutual interactions. The number
of combinations may very well grow with the identification of the
ligands for fas, 0X40, CD27, 4-1BB, and the low-affinity NGF
receptor, as NGF does not seem to be the natural ligand for this
molecule (28). Chemical cross-linking experiments using TNFa as
a probe have given no evidence that it binds with high affinity to
surface proteins other than the two known TNF receptors (29).
However, recent experiments (30) have shown that among 15
cytokines tested, TNFa was the only one able to enhance
IL-4-induced synthesis of germline e transcripts, a characteristic
activity of CD40L Therefore, it is not totally unreasonable to
speculate that the TNFs and CD40L could interact with each others'
receptors under some circumstances.
Finally, it is worth pointing out that, although the receptor-binding
domains of TNFa, TNF/3 and CD40L are extremely similar in
structure, the N-terminal domains of the proteins are quite different
TNF/3 is a classical secreted protein containing a signal peprjde,
and no transmembrane form of it has ever been detected. TNFa,
on the other hand, is synthesized as a type II transmembrane protein
(24) and then undergoes post-translational cleavage, liberating the
extracellular domain (i.e. the trimer) as a soluble effector.
Nevertheless, a substantial amount of TNFa remains membrane-
associated. CD40L seems to be at the other end of the spectrum,
in that is has not yet been detected as a naturally occurring secretory
product (10). Ironically, it may function as a receptor for one of the
many known soluble forms of members of the TNF receptor family
(7). The multiple interactions between TNF-like molecules and their
increasingly diverse receptors should prove to be a rich source of
surprises and complexities for years to come.
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Fig. 6. Cutout stereo view of a portion of the monomer contact region. The tyrosines (Y169) forming the triple hydrogen bonds (stippled lines) are
prominent in this view.
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Methods Include information pertaining to all FACS data in
Methods.
Cytometer. Identify the flow cytometer and describe its set-up.
Reagents. Identify all reagents. For antibody reagents include
the antigen name, the specific hybridoma, and the appropriate
reference (e.g. B220/RA3-6B2). Identify which fluorophores are being
used. Identify any second step reagents (e.g. Texas Red - Avidin).
Calibration. Describe the calibration of the cytometer. Include
the type of particles used and the method for setting the calibration
points (e.g. computer program, 'by eye'). If the machine has not been
calibrated, so state.
Software. Identify the software package(s) and algorithm^) used
to generate the plots. Identify the types of contours used, e.g.
probability (%), log (%). Fully describe any user selected parameters.
Gating. Describe any hard or soft gates that are common to all
plots (e.g. viable lymphocytes are shown after gating on forward and
side scatter and propidium iodide). Describe the quantification of
specific populations. For frequency data, indicate which populations
are used for both the numerator and denominator (e.g. total cells,
total lymphocytes defined by scatter gates).
Figures
Axes.
Scale. Clearly mark the scale intensities. It is inadequate to simply
state log or linear. Channel numbers are not acceptable.
Parameter. Clearly identify the parameter for each axis, e.g.
forward-scatter, £D4,"Pfopidium -iodide. -
Gating. Draw appropriate gates on the figures when pertinent.
Legend.
Identify the tissues analyzed and other appropriate information.
Specifics. Include specifics about the reagents (e.g. PE-B22O),
contours, and gating that are not apparent from Methods.
